Chaper 1-52, with Practice Questions and Correct Answers.

pg. 1 Advanced Pharmacology and Pharmacotherapeutics/ All Chaper 1-52, with Practice Questions and Correct Answers.Updated 2024-2025. Rated A+

Chapter i1. iThe iRole iof ithe iNurse Practitioner Multiple iChoice Identify ithe ichoice ithat ibest icompletes ithe istatement ior ianswers ithe i question.

1. Nurse ipractitioner iprescriptive iauthority iis iregulated iby:

1 .The iNational iCouncil iof iState iBoards iof iNursing 2 .The iU.S. iDrug iEnforcement iAdministration 3 .The iState iBoard iof iNursing ifor ieach istate

4 .The iState iBoard iof iPharmacy

• The ibenefits ito ithe ipatient iof ihaving ian iAdvanced iPractice iRegistered iNurse i(APRN) iprescriber iinclude:

1 .Nurses iknow imore iabout iPharmacology ithan iother iprescribers ibecause ithey itake iti iboth iin itheir ibasic inursing iprogram iand iin itheir iAPRN iprogram.2 .Nurses icare ifor ithe ipatient ifrom ia iholistic iapproach iand iinclude ithe ipatient iin decision imaking iregarding itheir icare .3 .APRNs iare iless ilikely ito iprescribe inarcotics iand iother icontrolled isubstances.4 .APRNs iare iable ito iprescribe iindependently iin iall istates, iwhereas ia iphysician’s assistant ineeds ito ihave ia iphysician isupervising itheir ipractice.

i3. Clinical ijudgment iin iprescribing iincludes:

1 .Factoring iin ithe icost ito ithe ipatient iof ithe imedication iprescribed

2 .Always iprescribing ithe inewest imedication iavailable ifor ithe idisease iprocess 3 .Handing iout idrug isamples ito ipoor ipatients 4 .Prescribing iall igeneric imedications ito icut icosts 1 / 4

pg. 2

4. Criteria ifor ichoosing ian ieffective idrug ifor ia idisorder iinclude:

• Asking ithe ipatient iwhat idrug ithey ithink iwould iwork ibest ifor ithem
• . Consulting inationally irecognized

iguidelines ifor idisease imanagement

• Prescribing imedications ithat iare iavailable ias isamples ibefore iwriting ia

iprescription

• Following iU.S. iDrug iEnforcement iAdministration iguidelines ifor iprescribing
• Nurse ipractitioner ipractice imay ithrive iunder ihealth-care ireform ibecause iof:

1 .The idemonstrated iability iof inurse ipractitioners ito icontrol icosts iand iimprove

patient ioutcomes 2 .The ifact ithat inurse ipractitioners iwill ibe iable ito ipractice iindependently 3 .The ifact ithat inurse ipractitioners iwill ihave ifull ireimbursement iunder ihealth-care reform

4 .The iability ito ishift iaccountability ifor iMedicaid ito ithe istate ilevel

Chapter i2. iReview iof iBasic iPrinciples iof iPharmacology

Multiple iChoice Identify ithe ichoice ithat ibest icompletes ithe istatement ior ianswers ithe i question.

i1. A ipatient’s inutritional iintake iand ilaboratory iresults ireflect ihypoalbuminemia. iThis iis icritical ito iprescribing ibecause:

1 .Distribution iof idrugs ito itarget itissue imay ibe iaffected .

2 .The isolubility iof ithe idrug iwill inot imatch ithe isite iof iabsorption.3 .There iwill ibe iless ifree idrug iavailable ito igenerate ian ieffect.4 .Drugs ibound ito ialbumin iare ireadily iexcreted iby ithe ikidneys.

i2. Drugs ithat ihave ia isignificant ifirst-pass ieffect:

1 .Must ibe igiven iby ithe ienteral i(oral) iroute ionly 2 .Bypass ithe ihepatic icirculation 2 / 4

pg. 3 3 .Are irapidly imetabolized iby ithe iliver iand imay ihave ilittle iif iany idesired iaction

4 .Are iconverted iby ithe iliver ito imore iactive iand ifat-soluble iforms

3. The iroute iof iexcretion iof ia ivolatile idrug iwill ilikely ibe ithe:

1 .Kidneys 2 .Lungs

3 .Bile iand ifeces 4 .Skin

• Medroxyprogesterone i(Depo iProvera) iis iprescribed iintramuscularly i(IM) ito icreate ia istorage ireservoir iof ithe idrug. Storage ireservoirs:

1 .Assure ithat ithe idrug iwill ireach iits iintended itarget itissue 2 .Are ithe ireason ifor igiving iloading idoses . 3

Increase ithe ilength iof itime ia idrug iis iavailable iand iactive

4 .Are imost icommon iin icollagen itissues

• The iNP ichooses ito igive icephalexin ievery i8 ihours ibased ion iknowledge iof ithe idrug’s:

1 .Propensity ito igo ito ithe itarget ireceptor .2

Biological ihalf-life

3 .Pharmacodynamics 4 .Safety iand iside ieffects

• Azithromycin idosing irequires ithat ithe ifirst iday’s idosage ibe itwice ithose iof ithe iother i4 idays iof ithe iprescription. iThis

iisconsidered i ia iloading idose. iA iloading idose:

1 .Rapidly iachieves idrug ilevels iin ithe itherapeutic irange

2 .Requires ifour- ito ifive-half-lives ito iattain 3 .Is iinfluenced iby irenal ifunction 4 .Is idirectly irelated ito ithe idrug icirculating ito ithe itarget itissues

• The ipoint iin itime ion ithe idrug iconcentration icurve ithat iindicates ithe ifirst isign iof ia itherapeutic ieffect iis ithe: 3 / 4

pg. 4

• Phenytoin irequires ithat ia itrough ilevel ibe idrawn. iPeak iand itrough ilevels iare idone:

1 .When ithe idrug ihas ia iwide itherapeutic irange 2 .When ithe idrug iwill ibe iadministered ifor ia ishort itime ionly 3 .When ithere iis ia ihigh icorrelation ibetween ithe idose iand isaturation iof ireceptor isites 4 .To idetermine iif ia idrug iis iin ithe itherapeutic irange

• A ilaboratory iresult iindicates ithat ithe ipeak ilevel ifor ia idrug iis iabove ithe iminimum itoxic iconcentration. iThis imeans

ithatthe: i

1 .Concentration iwill iproduce itherapeutic ieffects . 2

Concentration iwill iproduce ian iadverse iresponse

3 .Time ibetween idoses imust ibe ishortened 4 .Duration iof iaction iof ithe idrug iis itoo ilong

• Drugs ithat iare ireceptor iagonists imay idemonstrate iwhat iproperty?

1 .Irreversible ibinding ito ithe idrug ireceptor isite 2 .Upregulation iwith ichronic iuse 3 .Desensitization ior idownregulation iwith icontinuous iuse

4 .Inverse irelationship ibetween idrug iconcentration iand idrug iaction

• Drugs ithat iare ireceptor iantagonists, isuch ias ibeta iblockers, imay icause:

1 .Downregulation iof ithe idrug ireceptor . 2

An iexaggerated iresponse iif iabruptly idiscontinued

1 .Minimum iadverse ieffect ilevel Peak iof iaction . 2 3 .Onset iof iaction

4 .Therapeutic irange

• / 4